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Abstract: Extraskeletal myxoid chondrosarcoma (EMC) is an extremely rare soft tissue sarcoma,
marked by a translocation involving the NR4A3 gene. EMC is usually indolent and moderately
sensitive to anthracycline-based chemotherapy. Recently, we reported on the therapeutic activity of
sunitinib in a series of EMC cases, however the molecular target of sunitinib in EMC is unknown.
Moreover, there is still the need to identify alternative therapeutic strategies. To better characterize this
disease, we performed whole transcriptome sequencing in five EMC cases. Peculiarly, in one sample,
an in-frame deletion (c.1735_1737delGAT p.D579del) was identified in exon 11 of KIT. The deletion
was somatic and heterozygous and was validated both at DNA and mRNA level. This sample
showed a marked high expression of KIT at the mRNA level and a mild phosphorylation of the
receptor. Sanger sequencing of KIT in additional 15 Formalin Fixed Paraffin Embedded (FFPE) EMC
did not show any other mutated cases. In conclusion, exon 11 KIT mutation was detected only in
one out of 20 EMC cases analyzed, indicating that KIT alteration is not a recurrent event in these
tumors and cannot explain the EMC sensitivity to sunitinib, although it is an actionable mutation in
the individual case in which it has been identified.
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1. Introduction
Extraskeletal myxoid chondrosarcoma (EMC) is an extremely rare soft tissue sarcoma, marked
by a translocation involving the NR4A3 gene [1,2]. In most cases (about 62–75%), NR4A3 fuses with
EWSR1 on chromosome 22 [3], and less frequently (27%) with TAF15 on chromosome 17. More rarely,
other fusion partners of NR4A3 were identified, namely TCF12, TFG, and HSPA8 [3–7].
Despite the high risk of metastases (about 40%), EMC are usually indolent with 10-year
survival ranging between 65% and 85% [8,9]. Generally, these sarcomas are moderately sensitive to
anthracycline-based chemotherapy [10], and therefore there is an urgent need to identify alternative
therapeutic strategies [8–10]. Recently, we reported the therapeutic activity of sunitinib in a cohort of
10 EMC patients with 6 partial responses, 2 stable disease, and 2 showed progression. In that series,
the two progressive patients upon treatment were those carrying a TAF15-NR4A3 fusion, while all the
others were EWSR1-positive [11,12]. EMC tumor specimens showed RET proto-oncogene expression
and activation, while no other predictive biological markers of response were identified [12,13].
To further investigate the molecular alterations present in EWSR1-positive EMC cases, we performed
whole transcriptome sequencing (WTS) in a small series of EMC, identifying a case carrying an
activating KIT mutation and the recurrence of this event was evaluated in a larger series.
2. Results and Discussion
WTS was performed on five cases of EMC positive for EWSR1-NR4A3 fusion. Presence of the
chimeric mRNA was confirmed and no additional fusion event was identified. In concordance with
previous findings, as reported in the COSMIC database (available online: cancer.sanger.ac.uk/cosmic),
exon12/exon3 EWSR1-NR4A3 fusion was the most frequent breakpoint in our cohort. In particular,
the exon12/exon3 junction was detected in three out of five cases (#2, #3, #5) while exon13/exon3
and exon7/exon2 were detected respectively in samples #4 and #1 (Figure 1). All fusions retained the
coding frame for creating a chimeric protein, with the exception of sample #1, in which EWSR1 fuses
with exon2 of NR4A3, an exon upstream of the start codon.
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Pathogenic single nucleotide variants (SNV) and insertions and deletions (INDEL) were searched
starting from WTS data. Interestingly, in one case an in-frame deletion (c.1735_1737delGAT p.D579del)
was detected in the juxtamembrane domain (exon 11) of the KIT receptor (Figure 2A). The mutation
was somatic and heterozygous, and was validated both at the DNA and mRNA level through Sanger
sequencing (Figure 2B). This EMC case showed epithelioid morphology with cells arranged in cords
and strands (Figure 2C), with diffuse cytoplasmic and membranous immunohistochemical positivity
for KIT (Figure 2D). We evaluated the KIT expression using WTS data, finding that sample #1 had
an extremely high mRNA level, about 9.8-fold greater than in the other EMC cases (Figure 2E).
At the protein level, KIT was found to be expressed in all three EMC samples tested, while a mild
phosphorylation of KIT was detected only in the KIT mutated case (Figure 2F).
Int. J. ol. Sci. 2018, 19, x FOR PEER REVIEW   f 7 
 
Pathogenic single nucleotide variants (SNV) and insertions and deletions (INDEL) were 
searched starting from WTS data. Interestingly, in one case an in-frame deletion (c.1735_1737delGAT 
p.D579del) was detected in the juxtamembrane domain (exon 11) of the KIT receptor (Figure 2A). 
The mutation was somatic and heterozygous, and was validated both at the DNA and mRNA level 
through Sanger sequencing (Figure 2B). This EMC case showed epithelioid morphology with cells 
arranged in cords and strands (Figure 2C), with diffuse cytoplasmic and membranous 
immunohistochemical positivity for KIT (Figure 2D). We evaluated the KIT expression using WTS 
data, finding that sample #1 had an extremely high mRNA level, about 9.8-fold greater than in the 
other EMC cases (Figure 2E). At the protein level, KIT was found to be expressed in all three EMC 
samples tested, while a mild phosphorylation of KIT was detected only in the KIT mutated case 
(Figure 2F). 
 
Figure 2. Identification of a KIT exon 11 deletion in one case of EMC. (A) WTS reads supporting the 
deletion. Blue and pink bars represented the reads (respectively sense and antisense to the reference). 
Black lines that interrupt the alignment of the reads represent the deletion of three bases, 
corresponding to p.D579del. (B) Sanger sequencing validation of the mutation at mRNA and DNA 
level (upper and lower panel). In tumor specimens, the overlapping of two signals, starting after the 
TAT codon, demonstrated the presence of the heterozygous deletion corresponding to p.D579del. 
(C) Hematoxylin and eosin stain, and (D) immunohistochemistry evaluation of KIT in Sample #1. 
Scale-bars indicate 50 μm (E) Expression level of KIT mRNA was evaluated through counts per 
million (CPM) analysis from WTS data. Each red circle correspond to one of the five EMC case 
analyzed: sample #1 is indicated. (F) Detection of KIT protein expression and phosphorylation 
through western blot on three EMC cases. Relative quantification of band intensity is shown under 
each blot. Actin was used as the loading control. 
KIT encodes a receptor tyrosine kinase, which is often mutated in gastrointestinal stromal 
tumors (GIST) and represents the target and rationale of tyrosine kinase inhibitors (TKI) treatment in 
this tumor. While 85% of GISTs are characterized by alteration of KIT, more rarely (5–10% of cases) 
they can harbor activating mutations of platelet derived growth factor receptor alpha (PDGFRA) 
[14,15].  
Figure 2. Identification of a KIT exon 11 deletion in one case of EMC. (A) WTS reads supporting the
deletion. Blue and pink bars represented the reads (respectively sense and antisense to the reference).
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KIT encodes a receptor tyrosine kinase, which is often mutated in gastrointestinal stromal tumors
(GIST) and represents the target and rationale of tyrosine kinase inhibitors (TKI) treatment in this
tumor. While 85% of GISTs are characterized by alteration of KIT, more rarely (5–10% of cases) they
can harbor activating mutations of platelet derived growth factor receptor alpha (PDGFRA) [14,15].
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With the aim to evaluate the frequency of the involvement of KIT or PDGFRA alterations in EMC,
an additional cohort of 15 EMC were collected. Through Sanger sequencing, we analyzed all the
known hotspot exons of KIT and PDGFRA throughout the entire cohort, however we failed to detect
any other mutated case in addition to sample #1. These data supported the hypothesis that alterations
of KIT/PDGFRA are extremely rare in EMC.
In GIST, the location of the KIT mutation is clinically relevant as it influences the response to
imatinib. Mutations of KIT exon 11 are the most frequent GIST (about 70%), and generally they are the
most sensitive to imatinib [15]. The p.D579del, described in this EMC case, is a known gain-of-function
mutation of KIT through disruption of the autoinhibitory function of the juxtamembrane domain [16],
and it was already reported in several cases of GIST and of melanoma (COSM1294). Moreover, it was
also described in a metastatic case of sinonasal carcinoma and in a heavily pretreated thymic carcinoma.
Noticeably, also in these two types of tumors, authors observed a relevant disease stabilization under
imatinib [17,18]. The EMC patient with a KIT exon 11 mutation described here never received imatinib.
Thus, the therapeutic role of this agent in this case is still to be defined. Interestingly the same patient
had been treated with sunitinib with a prolonged response. Unfortunately, the KIT exon 11 mutation
was found only in one case out of 20, and therefore cannot explain the other high frequency of responses
to sunitinib that have been observed, although it cannot be ruled out that it may have favored the
response in this single case.
3. Materials and Methods
3.1. Samples
Five EWSR1-NR4A3 positive EMCs were collected for WTS analysis. As validation analysis, we
evaluated the frequency of a KIT alteration in EMC in an additional retrospective cohort of 15 FFPE
cases. The study was approved by the local ethics committee, and informed written consent was
obtained in all cases, in accordance with national legislation and the Helsinki Declaration (27 May 2014,
Prot. INT 54/13). Sample characteristics are shown in Supplementary Materials Table S1.
3.2. Whole Transcriptome Sequencing
For WTS analysis, total RNA was extracted from tumor specimens with RNeasy Mini Kit (Qiagen,
Milan, Italy), then cDNA libraries were synthesized from 250 ng of total RNA with TruSeq RNA
Sample Prep Kit v2 (Illumina, San Diego, CA, USA) according to the manufacturer’s recommendations.
Briefly, poly(A)-RNA molecules were purified using oligo-dT magnetic beads, then mRNA was
fragmented and randomly primed for reverse transcription, followed by second-strand synthesis to
create double-stranded cDNA fragments. The generated cDNA fragments went through a terminal-end
repair process and ligation using paired-end sequencing adapters, then amplified to create the final
cDNA library. WTS libraries were quality-checked and sized with Agilent DNA 7500 chips on the
Bioanalyzer 2100 (Agilent Technologies, Milan, Italy), then quantified using a fluorometric assay
(QuantITPicogreen assay, Thermo Fisher, Monza, Italy). Then, 12 pM paired-end libraries were
amplified and ligated to the flowcell by bridge PCR, and sequenced at 2 × 80 bp read length for WTS,
using Illumina Sequencing by synthesis (SBS) technology.
3.3. Bioinformatic Analysis
After demultiplexing and FASTQ generation, the paired-end reads were trimmed using
AdapterRemoval (available online: https://github.com/MikkelSchubert/adapterremoval). Sequences
were mapped to HG38 with the TopHat/BowTie (available online: https://ccb.jhu.edu/software/
tophat/) and the PCR and optical duplicates were removed with the function rmdup of Samtools
(available online: https://samtools.sourceforge.net). For fusion genes detection, DeFuse (available
online: https://sourceforge.net/projects/defuse), ChimeraScan (available online: http://chimerascan.
googlecode.com), Tophatfusion (available online: https://ccb.jhu.edu/software/tophat/fusion_
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index.html), and FusionMap (available online: http://www.omicsoft.com/fusionmap) were used.
Variation calling was performed with SAMtools and SNVMix2, thus identifying all the point
mutations, insertions, and deletions present in the sample (SNV and InDels). Variants present
in dbSNP, Exac, and Exome Variant Server (EVS) with frequency greater than 1% were excluded.
For evaluation of KIT gene expression level, htseq-count function (Python package Htseq—available
online: http://www.huber.embl.de/HTSeq/doc/overview.html) was used.
3.4. Sanger Sequencing
KIT and PDGFRA hotspot exons were sequenced through Sanger method in these cases and in
an additional cohort of 15 EMC FFPE samples. DNA was extracted with a QiAmp DNA Mini Kit
(Qiagen, Milan, Italy) from fresh frozen tissue and with QiAmp DNA Micro Kit (Qiagen)) for FFPE.
Respectively, 10 and 20 ng of DNA was used for PCR using primers specific for exons 8, 9, 11, 13, 14,
and 17 of KIT, and for exons 12, 14, and 18 of PDGFRA (Supplementary Materials Table S2). Amplicons
were then purified and sequenced on a ABI3730 Genetic Analyzer (Applied Biosystems, Monza, Italy).
3.5. Immunohistochemistry
KIT protein expression was assessed by immunohistochemistry on FFPE 3 µm slides
using c-kit (Ab CD117, A4502, Agilent Technologies Dako, Milan, Italy) with an automated
immunostainer (BenchMark Ultra, Ventana Medical Systems Inc., Tucson, AZ, USA) according to
manufacturer’s instructions.
3.6. Western Blot
Frozen tumor samples were homogenized in a RIPA buffer containing phosphatase and protease
inhibitors (Halt™ Protease and Phosphatase Inhibitor Cocktail, ThermoFisher) and immunoblotted.
ImageJ (available online: https://imagej.nih.gov/ij/) was used for signal quantification and relative
quantification was calculated in comparison with β-Actin. The following primary antibodies were
used: CD117 (A4502, Agilent Technologies Dako), Phospho-c-KIT (#3391, Cell Signaling, Leiden,
The Netherlands), β-Actin (A1978, Sigma-Aldrich, Milan, Italy).
4. Conclusions
In conclusion, this is the first report of the presence of KIT exon 11 mutations in EMC. This event
was detected in one out of 20 EMC cases analyzed, indicating that a KIT alteration is not a recurrent
event in EMC, and cannot explain the EMC sensitivity to sunitinib, although it is an actionable mutation
in the individual case in which it has been identified.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/7/1855/
s1.
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